Figure 2.

Change from baseline in FEV₁ AUC_0–24, FEV₁ AUC_12–24, and FEV₁ AUC_0–12 compared with placebo (A) on day 1 and (B) at week 6 (ITT population). Data reported as LS mean (95% CI) differences from placebo (ANCOVA). ^‡p < 0.001; ^§p < 0.0001 for aclidinium or tiotropium versus placebo. ^¶p < 0.05; ^#p < 0.01 for aclidinium versus tiotropium. ANCOVA, analysis of covariance; AUC, area under the curve; AUC_0–24, AUC over the 24-hour period post-morning treatment; AUC_12–24, AUC over the nighttime period; AUC_0–12, AUC for the 12-hour period post-morning treatment; BID, twice daily; CI, confidence interval; FEV₁, forced expiratory volume in 1 second; ITT, intent-to-treat; LS, least squares; QD, once daily.